Nativis Announces Publication of Study in Patients with Recurrent Glioblastoma (rGBM)
The publication of the study, An Early Feasibility Study of the Nativis Voyager Device in Patients with Recurrent Glioblastoma: First Cohort in US, may be viewed HERE or on the Nativis web site .
- The publication of the study, An Early Feasibility Study of the Nativis Voyager Device in Patients with Recurrent Glioblastoma: First Cohort in US, may be viewed HERE or on the Nativis web site .
- "The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but also that further studies to explore clinical utility are warranted."
- The Nativis Voyager produces ultra-low radio frequency energy (ulRFE) intended to induce a biologic response in solid tumors, such as rGBM.
- The Nativis Voyager system is an investigational medical device, limited by United States law to investigational use only.